NCT03568448View on ClinicalTrials.gov

Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging

Active, not recruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

April 16, 2018

Primary Completion Date

January 22, 2020

Study Completion Date

December 31, 2027

Conditions
HER2 Negative Breast Cancer
Interventions
OTHER

Response monitoring (no intervention)

Response monitoring (no intervention)

Trial Locations (1)

87131

University of New Mexico Comprehensive Cancer Center, Albuquerque

All Listed Sponsors
lead

New Mexico Cancer Research Alliance

OTHER

NCT03568448 - Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging | Biotech Hunter | Biotech Hunter